|Mr. Yujiro S. Hata||Co-Founder, CEO, Pres & Director||575k||N/A||1974|
|Mr. Paul A. Stone||CFO, Gen. Counsel & Principal Accounting Officer||351.55k||N/A||1964|
|Dr. Julie Hambleton||Sr. VP, Chief Medical Officer & Head of Devel.||285.43k||N/A||1958|
|Mr. Jeffrey Hager||Sr. VP, CTO, Head of Target Discovery & External Innovation||N/A||N/A||1964|
|Mr. Michael P. Dillon||Sr. VP, Chief Scientific Officer & Head of Research||N/A||N/A||1967|
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A in tumor cells having MTAP gene deletions; Pol-theta in tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations; PARG in tumors with genetic mutations in base excision repair; and WRN in high microsatellite instability tumors. The company was founded in 2015 and is headquartered in South San Francisco, California.
IDEAYA Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.